Trending Topic

14 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Acute myeloid leukaemia (AML) is a heterogeneous haematologic cancer associated with clonal expansion of myeloid blasts in the bloodstream, bone marrow and other tissues. AML is associated with blasts expressing various complex molecular and cytogenetic alterations, which play an important role in disease prognostication. The median age of AML diagnosis is 67 years with nearly […]

John Marshall, ASCO GI22: Recent Advances in Upper Gastrointestinal Cancers

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Mar 8th 2022

touchONCOLOGY were thrilled to speak to Editorial Board member Professor John Marshall (Medstar Georgetown University Hospital, Washington, DC, USA) to summarise the latest developments and data from the ASCO Gastrointestinal Cancers Symposium 2022.

The phase III CheckMate 577 Study (NCT03044613): https://meetings.asco.org/abstracts-presentations/204867

KEYNOTE-062 (NCT02494583): https://meetings.asco.org/abstracts-presentations/204515

JCOG NExT study (UMIN000014795): https://meetings.asco.org/abstracts-presentations/204882

Questions:

  1. Could you give us a brief overview of neoantigen based therapies and their clinical development to date in upper gastrointestinal cancers? 00:16-02:41
  2. Which other recent advances in upper gastrointestinal cancers would you like to highlight? 02:47-3:57

Speaker Disclosure: John Marshall has no conflicts of interest to declare in relation to this video.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.

Filmed in coverage of the ASCO Gastrointestinal Cancers Symposium 2022.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup